Atossa Sees Q1 Operating Costs Climb 35% to $9.9M as FDA Awards Orphan, RPD Status for (Z)-Endoxifen
ATOS•Atossa reported Q1 operating expenses of $9.9M, up $2.5M year-over-year, driven by a 35% rise in clinical and preclinical trial costs for (Z)-endoxifen. FDA granted Orphan Drug status for (Z)-endoxifen in Duchenne muscular dystrophy and Rare Pediatric Disease designation in McCune-Albright syndrome, eligible for PRVs up to $205M.
1. Q1 Financial Results
Atossa reported total operating expenses of $9.9M for the quarter ended March 31, 2026, an increase of $2.5M from $7.4M in Q1 2025. Research and development spending rose 15% to $4.8M, driven by a 35% jump in clinical and preclinical trial costs related to (Z)-endoxifen.
2. Regulatory and Corporate Developments
FDA granted Orphan Drug designation for (Z)-endoxifen in Duchenne muscular dystrophy and Rare Pediatric Disease designation for McCune-Albright syndrome, making the therapy eligible for priority review vouchers valued at $100M–$205M. The company also bolstered its clinical leadership team with two new medical directors in oncology and rare diseases.
